At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating 89Zr- DFO-MSTP2109A and 89Zr DFO-MSTP2109A for Prostate Cancer. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long 89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts. DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells. Attached to the DFO-MSTP2109A is a radioactive material called 89ZR, which allows it to be imaged by a PET scanner. The results of this study may help researchers know whether 89Zr-DFO-MSTP2109A can be used as a diagnostic agent for finding prostate cancer that have STEAP1 on its surface with a PET scanner. The reason why identifying STEAP1 on prostate cancer cells is that new therapies are being developed to target STEAP1 prostate cancer cells.
Study Details
Timeline
Interventions
If you are enrolled onto Group 1: Once you are given the diagnostic agent, the following procedures will be done: PET scans at the approximate times: * 1-4 hours after the injection * 24 hours after the injection (the next day, Day 2) * 48-120 hours after the injection (on either Day 3, 4, or 5) * 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days, * Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection. * At each time of your scheduled PET scan.
If you are enrolled onto Group 2: Once you are given the study drug, the following procedures will be done: You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection). No research blood work will be drawn in Group 2